Posts by: Kevin Perez

Kevin Perez

Kevin Perez holds a MS in Computer Science from New York University (NYU) and a MS in Biomedical Sciences from Paris Descartes University. He is interested in biomedical data analysis and bringing the latest biomedical research news to patients.

September 25, 2017September 25, 2017

UK’s NICE Approves Opdivo as Second-line NSCLC Treatment through Cancer Drugs Fund

News

Non-small cell lung cancer patients in England and Wales who failed prior chemotherapy can now access Opdivo (nivolumab) as a second-line treatment, following the therapy’s recent approval by the U.K.’s National ... Read more

September 13, 2017

Experts Discuss Role of Cancer Immunotherapy at Bristol-Myers Presentation, Panel Discussion

News

In just three years, Bristol-Myers Squibb (BMS) received more than 10 approvals for Opdivo (nivolumab), authored 12 publications in the New England Journal of Medicine, and was granted seven Breakthrough Therapy designations by the ... Read more

September 11, 2017

Imugene Begins Phase 1b/2 Clinical Trial of HER-Vaxx Vaccine for Stomach Cancer

News

The first patient has been dosed in a Phase 1b/2 trial evaluating Imugene’s stomach cancer vaccine HER-Vaxx. Researchers are still recruiting participants. They hope to enroll 18 patients at eight locations ... Read more

September 5, 2017September 5, 2017

Bristol-Myers Squibb, Daiichi Sankyo to Jointly Test Opdivo/DS-8201 Combo in HER2+ Metastatic Breast, Bladder Cancers

News

Bristol-Myers Squibb has formed a partnership with Japan’s Daiichi Sankyo to test Opdivo (nivolumab) in combination with DS-8201 in HER2-positive metastatic breast and bladder cancer. Opdivo, a blockbuster anti-PD-1 immune checkpoint inhibitor, is already approved ... Read more